Skip to main content
. 2021 Feb 18;35(2):451–461. doi: 10.1007/s40620-021-00981-8

Table 3.

Hematological and renal response to eculizumab therapy in six sTMA patients

Characteristic Baseline 4 weeks 6 months Last FU
Anemia 6 (100%) 6 (100%) 4 (66.6%) 5 (83.3%)
Mean Hb (g/dL) 8.2 (± 1.4) 9.6 (± 1) 11.4 (± 1.1) 10.8 (± 2.2)
Thrombopenia 5 (83.3%) 4 (66.7%) 1 (25%) 2 (33.3%)
Mean PLT count (G/L) 100 (± 139) 122 (± 128) 191 (± 69) 177 (± 94)
Mean LDH (U/L) 635 (± 378) 528 (± 530) 221 (± 82) 388 (± 445)
AKI 6 (100%) n.a n.a n.a
RRT 4 (66.7%) 3 (50%) 1 (16.6%) 1 (16.6%)
Mean SCr (mg/dL) 3.8 (± 1.87) 3.56(± 0.74) 2.69 (± 0.54) 2.18 (± 0.44)
Mean PKR (mg/g) 694 (± 969) n.a.a 428 (± 226) 196 (± 95)
KTX 0 0 0 0
Patients on Ecu therapy 6 (100%) 4 (66.6%) 2 (33.3) 0
Lost to FU 0 0 0 2 (33.3%)

Numbers are count and percent or mean and standard deviation

sTM secondary thrombotic microangiopathy, FU follow-up, Hb hemoglobin, PLT platelets, LDH lactate dehydrogenase, SCr serum creatinine, PKR protein-creatinine ratio, RRT renal replacement therapy, KTX kidney transplantation, Ecu eculizumab

aData only available for 1 patient. Anemia was defined as Hb levels of < 12.5 g/dL for female and < 13.5 g/dL for male patients. Thrombopenia was defined as platelet count < 150 G/L